https://www.selleckchem.com/products/th1760.html Abbreviations 3-MA 3-methyladenine; APEX a modified soybean ascorbate peroxidase; ATG5 autophagy related 5; ATG9A autophagy related 9A; ATG12 autophagy related 12; BHK baby hamster kidney; C-exosomes caveolin-exosomes; CAMKK2/CAMKKβ calckum/calmodulin dependent protein kinase kinase 2; CAV1 caveolin 1; DAB 3,3'-diaminobenzidine; DAPK death associated protein kinase; EEA1 early endosome antigen 1; EM electron microscopy; FCS fluorescence correlation spectroscopy; GBP GFP/YFP-binding peptide; GFP green fluorescent protein; GOLGA2 golgin A2; ILVs intralumenal vesicles; LC3 microtubule-associated protein 1 light chain 3; MBP maltose binding protein; MTORC1 mechanistic target of rapamycin kinase complex 1; MVBs multivesicular bodies; PBS phosphate-buffered saline; PCa prostate cancer; PI3K phosphoinositide 3-kinase; PM plasma membrane; SFM serum-free medium; TSG101 tumor susceptibility 101; WCL whole cell lysates; WT wild type; YFP yellow fluorescent protein; βoG β-octylglucoside. Recently, the CARMENA and SURTIME studies, suggested that upfront cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and high-risk metastatic renal cell carcinoma (mRCC). However, CN remains an indication in low-risk and when immediate systemic treatment is not required. The aim was to evaluate the long-term overall survival (OS) in patients with primary mRCC, based on the first line treatment. There were 1483 patients with primary mRCC in the National Kidney Cancer Registry from 2005 to 2013. Data on primary treatment, TNM stage, RCC type, tumor size, patient age and sex were extracted. Survival time was calculated from time of diagnosis to time of death or until July 2019. Mann-Whitney U and Chi-square tests, the Kaplan-Meyer method and Cox regression analyses were used. Patients primary treated with CN had a significantly longer OS (  < .001) than patients primary treated with systemic therapy or palliation. In a